Vivos Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Vivos Therapeutics has a total shareholder equity of $411.0K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.7M and $10.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.64m |
| Equity | US$411.00k |
| Total liabilities | US$10.32m |
| Total assets | US$10.73m |
Recent financial health updates
Recent updates
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Apr 25
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be
May 21Vivos Therapeutics: First Take After The Broad Market Sell-Off
Mar 06Vivos Therapeutics: Reimagining Sleep
Jul 30Vivos Therapeutics prices $24M follow-on offering
May 07Financial Position Analysis
Short Term Liabilities: VVOS's short term assets ($2.5M) do not cover its short term liabilities ($7.3M).
Long Term Liabilities: VVOS's short term assets ($2.5M) do not cover its long term liabilities ($3.0M).
Debt to Equity History and Analysis
Debt Level: VVOS is debt free.
Reducing Debt: VVOS has no debt compared to 5 years ago when its debt to equity ratio was 12.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VVOS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VVOS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.9% each year